A recent study published in the online edition of the British Medical Journal (May 2012) shows that the vaginal ring has at least a sixfold increased risk of venous thrombosis as combined pills with desogestrel or drospirenone, which is about twice the risk among women using second-generation birth control pills.
The exhaustive and thorough study followed Danish women from 2001 to 2010. Researchers concluded the following:
“Women who use combined contraceptive transdermal patches are at an increased risk of venous thrombosis about eight times that of non-users of hormonal contraception, corresponding to 9.7 events per 10,000 exposure years. Vaginal rings increased the risk of venous thrombosis 6.5 times compared with non-use of hormonal contraception, corresponding to 7.8 events per 10,000 exposure years.”
To put these statistics in another perspective, Dr. Shezad Malik says that combined oral contraceptives with levonorgestrel or norgestimate (second generation birth control pills, which are not Yasmin or Yaz) have 50 percent of the risk of venous thrombosis than oral contraceptives containing desogestrel, gestodene, or drospirenone. Furthermore, women who use combined contraceptive transdermal patches are at an increased risk of venous thrombosis about eight times that of non-users of hormonal contraception.
READ MORE NUVARING BIRTH CONTROL LEGAL NEWS
The Danish researchers advise that women consider switching to a safer form of birth control. Given the now-proven fact that women are at an increased risk for NuvaRing blood clot, it is no wonder that NuvaRing lawsuits are increasing.